AIMS: AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected adults. The pharmacokinetics of OBV/PTV/r + DSV during raltegravir coadministration were also characterized. METHODS: Adults living with HIV/HCV coinfection receiving steady-state raltegravir (400 mg twice daily) with 2 nucleos(t)ide analogues were enrolled. Pharmacokinetics of raltegravir were assessed prior to HCV therapy, and 4 weeks later following initiation of OBV/PTV/r (25/150/100 mg) once daily + DSV (250 mg) twice daily. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were used to compare the following: raltegravir pharmacokinetics with HCV therapy (week 4) vs before HCV therapy (week 0); OBV/PTV/r and DSV pharmacokinetics vs historical healthy controls; raltegravir pharmacokinetics at week 0 vs historical control adults living with HIV. RESULTS: Eight of 11 participants had decreased raltegravir exposures after initiation of HCV therapy. The GMRs (90% CI) for maximum concentration and area under the concentration-time curve of raltegravir with vs without HCV therapy were 0.68 (0.38-1.19) and 0.82 (0.58-1.17), respectively. Comparing OBV/PTV/r pharmacokinetics in healthy controls, A5334s study participants demonstrated generally lower maximum concentration and area under the concentration-time curve values by 41-82% and 4-73%, respectively. Raltegravir exposures tended to be higher in A5334s study participants compared to adults living with HIV. CONCLUSIONS: The majority of participants' plasma raltegravir exposures were lower after initiation of HCV therapy in coinfected adults; however, confidence intervals were wide.
AIMS: AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected adults. The pharmacokinetics of OBV/PTV/r + DSV during raltegravir coadministration were also characterized. METHODS: Adults living with HIV/HCV coinfection receiving steady-state raltegravir (400 mg twice daily) with 2 nucleos(t)ide analogues were enrolled. Pharmacokinetics of raltegravir were assessed prior to HCV therapy, and 4 weeks later following initiation of OBV/PTV/r (25/150/100 mg) once daily + DSV (250 mg) twice daily. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were used to compare the following: raltegravir pharmacokinetics with HCV therapy (week 4) vs before HCV therapy (week 0); OBV/PTV/r and DSV pharmacokinetics vs historical healthy controls; raltegravir pharmacokinetics at week 0 vs historical control adults living with HIV. RESULTS: Eight of 11 participants had decreased raltegravir exposures after initiation of HCV therapy. The GMRs (90% CI) for maximum concentration and area under the concentration-time curve of raltegravir with vs without HCV therapy were 0.68 (0.38-1.19) and 0.82 (0.58-1.17), respectively. Comparing OBV/PTV/r pharmacokinetics in healthy controls, A5334s study participants demonstrated generally lower maximum concentration and area under the concentration-time curve values by 41-82% and 4-73%, respectively. Raltegravir exposures tended to be higher in A5334s study participants compared to adults living with HIV. CONCLUSIONS: The majority of participants' plasma raltegravir exposures were lower after initiation of HCV therapy in coinfected adults; however, confidence intervals were wide.
Authors: E J Smolders; S Pape; C T M M de Kanter; A P van den Berg; J P H Drenth; D M Burger Journal: Int J Antimicrob Agents Date: 2017-02-06 Impact factor: 5.283
Authors: Mohamad Shebley; Jinrong Liu; Olga Kavetskaia; Jens Sydor; Sonia M de Morais; Volker Fischer; Marjoleen J M A Nijsen; Daniel A J Bow Journal: Drug Metab Dispos Date: 2017-05-08 Impact factor: 3.922
Authors: Mark S Sulkowski; Joseph J Eron; David Wyles; Roger Trinh; Jay Lalezari; Chia Wang; Jihad Slim; Laveeza Bhatti; Joseph Gathe; Peter J Ruane; Richard Elion; Fritz Bredeek; Robert Brennan; Gary Blick; Amit Khatri; Krystal Gibbons; Yiran B Hu; Linda Fredrick; Gretja Schnell; Tami Pilot-Matias; Rakesh Tripathi; Barbara Da Silva-Tillmann; Barbara McGovern; Andrew L Campbell; Thomas Podsadecki Journal: JAMA Date: 2015 Mar 24-31 Impact factor: 56.272
Authors: Sara Croxford; Aileen Kitching; Sarika Desai; Meaghan Kall; Michael Edelstein; Andrew Skingsley; Fiona Burns; Andrew Copas; Alison E Brown; Ann K Sullivan; Valerie Delpech Journal: Lancet Public Health Date: 2016-12-15
Authors: David A Wohl; Julie B Dumond; Suzanne Blevins; Donna Pittard; David Ragan; Ruili Wang; Kelley Massengale; Kendall Walsh; Michelle Floris-Moore; Joseph J Eron; Amy Richardson; Michael G Hudgens; Angela D M Kashuba Journal: Antimicrob Agents Chemother Date: 2012-11-26 Impact factor: 5.191
Authors: Charles S Venuto; Yoninah S Cramer; Susan L Rosenkranz; Mark Sulkowski; David L Wyles; Daniel E Cohen; Jeffrey Schmidt; Beverly L Alston-Smith; Gene D Morse Journal: Br J Clin Pharmacol Date: 2019-12-12 Impact factor: 4.335